Opioid Overdose Clinical Trial
Official title:
Vending Machine Naloxone Distribution for Your Community (VENDY): Increasing Reach and Implementation of Naloxone Distribution
Vending machines are an innovative strategy shown to increase access to naloxone, a medication used to reverse opioid overdose. The aim of this proposal is to study the reach of a community-initiated, stakeholder engaged adaptation of naloxone distribution, VEnding machine Naloxone Distribution for Your community (VENDY) program.
Status | Not yet recruiting |
Enrollment | 1489 |
Est. completion date | January 1, 2026 |
Est. primary completion date | June 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Any person in the community who desires to obtain naloxone will be able to use the machines Exclusion Criteria: - Inability to enter a code on a vending machine or open a kiosk. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Colorado, Denver | Denver Health and Hospital Authority, Southern Colorado Harm Reduction Association, Summit County Public Health Department |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reach | Reach will be assessed using monthly counts of naloxone distribution in the 6 months before and after VENDY implementation. Naloxone counts will include distribution from all sources within the organization and captured through pharmacy fills from the electronic health record and distribution tracking logs. Naloxone machine distribution will be added to the total monthly count in the post implementation phase and obtained using the vending machine electronic software (reporting date and time of distribution) or (for kiosks) the staff monthly refill tracking log capturing quantity of naloxone kits required to fill the machine (captured at least monthly). | the 6 months pre VENDY implementation and the 6 months post VENDY implementation | |
Secondary | Adoption | Adoption is the percentage of sites placing a naloxone vending machine in the respective community that is made available for community members to obtain naloxone. | At the end of program development (program development is the first phase in which each site is developing VENDY over a 6-18 month period of time) | |
Secondary | Fatal Opioid Overdose Events-Effectiveness | The count of fatal opioid overdose events for each respective county in which the participating organization and vending machine reside in the year before and year after VENDY implementation. Overdose will be captured from publicly available data from death records reported by the Colorado Department of Public Health and Environment. To address temporality we will include fatal opioid overdose deaths in a comparison community matching community features (urban/rural status, community population, and opioid death rate). | pre-implementation in the year prior to a live VENDY program and post implementation in the year following live VENDY program | |
Secondary | Fidelity-Implementation | Fidelity is the percentage of time staff refill and maintain the machine per protocol as measured by the vending machine software and machine activity tracking log. | the 6 months following VENDY implementation | |
Secondary | Maintenance | Number of months each organization implementing VENDY continues to make naloxone available in the machines for the 6 months following the initial implementation phase (6 months). | the 6 months following the initial implementation phase (6 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04372238 -
The Rhode Island Prescription and Illicit Drug Study
|
N/A | |
Recruiting |
NCT03924505 -
Preventing Opioid Overdose Mortality in the United States
|
N/A | |
Completed |
NCT05093309 -
Preventing Opioid Overdose Deaths by Empowering Pharmacists to Dispense Naloxone
|
N/A | |
Completed |
NCT05219669 -
Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens
|
Phase 1 | |
Completed |
NCT04317053 -
Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program
|
Phase 3 | |
Not yet recruiting |
NCT06466005 -
UnityPhilly Response App for Overdose Reversal
|
||
Recruiting |
NCT04815590 -
Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose
|
||
Active, not recruiting |
NCT05096429 -
Preventing Overdose Using Information and Data From the Environment
|
N/A | |
Suspended |
NCT05114460 -
Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal
|
Phase 2 | |
Recruiting |
NCT06238128 -
Opioid Rapid Response System: Naloxone Training in Communities
|
N/A | |
Completed |
NCT02662153 -
Incidence and Predictors of Opioid Overdose and Death Among Long-Term Users of Opioid Analgesics
|
||
Active, not recruiting |
NCT05944133 -
Health Insurance Instability and Mortality Among Patients Receiving Bup Tx for OUD
|
||
Completed |
NCT05377255 -
Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults
|
Phase 1 | |
Recruiting |
NCT05877118 -
Improving Availability of Intranasal Naloxone
|
N/A | |
Recruiting |
NCT05072249 -
European Cohort Study of the Effectiveness of Take Home Naloxone
|
||
Withdrawn |
NCT05808881 -
Clinical Outcomes From Nalmefene
|
Phase 4 | |
Not yet recruiting |
NCT01622504 -
Naloxone Nasal Spray Pharmacokinetic Study
|
Phase 1 | |
Completed |
NCT05506267 -
Development of a Tracheal Sound Sensor
|
||
Completed |
NCT02535494 -
Risks and Benefits of Naloxone Prescribing
|
N/A | |
Not yet recruiting |
NCT06408714 -
Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose
|
Phase 3 |